NASDAQ:GILD - Gilead Sciences News Headlines

Sign in or create an account to add this stock to your watchlist.
$75.51 +0.68 (+0.91 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$75.51
Today's Range$74.75 - $75.93
52-Week Range$64.27 - $89.54
Volume9.57 million shs
Average Volume5.17 million shs
Market Capitalization$97.01 billion
P/E Ratio8.82
Dividend Yield3.05%
Beta1.02

Headlines

Gilead Sciences (NASDAQ GILD) News Headlines

Source:
DateHeadline
U.S. Probes Drugmakers Over Free ServicesU.S. Probes Drugmakers Over Free Services
www.wsj.com - September 21 at 2:15 PM
Molecular Templates Surges 50%, Inks Cancer Deal With TakedaMolecular Templates Surges 50%, Inks Cancer Deal With Takeda
finance.yahoo.com - September 20 at 3:02 PM
Novartis $372000 Cancer Drug Hits First Hurdle in EuropeNovartis $372000 Cancer Drug Hits First Hurdle in Europe
www.bloomberg.com - September 19 at 3:09 PM
Viking Therapeutics Liver Candidate Passes Test, Shares SoarViking Therapeutics Liver Candidate Passes Test, Shares Soar
finance.yahoo.com - September 19 at 3:09 PM
Is Gilead (GILD) a Suitable Stock for Value Investors Now?Is Gilead (GILD) a Suitable Stock for Value Investors Now?
finance.yahoo.com - September 19 at 3:09 PM
Gilead Faces Doubts on Wall Street a Year After $12 Billion DealGilead Faces Doubts on Wall Street a Year After $12 Billion Deal
finance.yahoo.com - September 19 at 3:09 PM
Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's SuccessBiotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success
finance.yahoo.com - September 19 at 3:09 PM
Agenus Receives Milestone Payment of $5 Million from IncyteAgenus Receives Milestone Payment of $5 Million from Incyte
finance.yahoo.com - September 19 at 6:31 AM
UK rejects adult Novartis CAR-T therapy, after yes in kidsUK rejects adult Novartis CAR-T therapy, after 'yes' in kids
finance.yahoo.com - September 19 at 6:31 AM
Health Care Digest: UCSFs ImmunoX revolution, Gileads deal, a pain breakthrough and moreHealth Care Digest: UCSF's ImmunoX revolution, Gilead's deal, a pain breakthrough and more
www.bizjournals.com - September 18 at 3:17 PM
Gilead: Forming A Base?Gilead: Forming A Base?
seekingalpha.com - September 18 at 3:17 PM
Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASHViking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASH
finance.yahoo.com - September 18 at 3:17 PM
The Funded: Two big shutdowns, 3 IPO filings and a Walmart acquisitionThe Funded: Two big shutdowns, 3 IPO filings and a Walmart acquisition
www.bizjournals.com - September 18 at 5:04 AM
3 High-Quality Biotech Companies for 4th Quarter3 High-Quality Biotech Companies for 4th Quarter
finance.yahoo.com - September 18 at 5:04 AM
Health Care Digest: UCSF's ImmunoX revolution, Gilead's deal, a pain breakthrough and moreHealth Care Digest: UCSF's ImmunoX revolution, Gilead's deal, a pain breakthrough and more
finance.yahoo.com - September 18 at 5:04 AM
Should Value Investors Pick Gilead Sciences (GILD) Stock?Should Value Investors Pick Gilead Sciences (GILD) Stock?
finance.yahoo.com - September 17 at 3:06 PM
Why Gilead Stock Is a Sleepy Giant Waiting to Break OutWhy Gilead Stock Is a Sleepy Giant Waiting to Break Out
www.msn.com - September 17 at 3:06 PM
FY2021 EPS Estimates for Gilead Sciences, Inc. (GILD) Raised by AnalystFY2021 EPS Estimates for Gilead Sciences, Inc. (GILD) Raised by Analyst
www.americanbankingnews.com - September 17 at 2:20 AM
Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.38 BillionGilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.38 Billion
www.americanbankingnews.com - September 15 at 1:36 AM
Unity (UBX) Catches Eye: Stock Jumps 8.8%Unity (UBX) Catches Eye: Stock Jumps 8.8%
finance.yahoo.com - September 14 at 3:11 PM
Fish & Richardson Principals Chad Shear and Jonathan Singer Named "2018 Winning Litigators" by The National Law JournalFish & Richardson Principals Chad Shear and Jonathan Singer Named "2018 Winning Litigators" by The National Law Journal
www.prnewswire.com - September 14 at 12:33 PM
A Brawl Is Brewing Between AbbVie and Gilead Sciences in ArthritisA Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
www.fool.com - September 14 at 7:28 AM
How Gilead Call Prices Tripled OvernightHow Gilead Call Prices Tripled Overnight
finance.yahoo.com - September 14 at 5:09 AM
Gilead taps Durham gene editing firm for $445M dealGilead taps Durham gene editing firm for $445M deal
finance.yahoo.com - September 14 at 5:09 AM
 Analysts Anticipate Gilead Sciences, Inc. (GILD) Will Announce Earnings of $1.62 Per Share Analysts Anticipate Gilead Sciences, Inc. (GILD) Will Announce Earnings of $1.62 Per Share
www.americanbankingnews.com - September 13 at 10:16 PM
Whats Next for Gilead Sciences After Its Latest Clinical SuccessWhat's Next for Gilead Sciences After Its Latest Clinical Success
www.msn.com - September 13 at 3:07 PM
Gilead Inks Gene Editing Collaboration Deal for HBV InfectionGilead Inks Gene Editing Collaboration Deal for HBV Infection
finance.yahoo.com - September 13 at 3:07 PM
Company News For Sep 13, 2018Company News For Sep 13, 2018
finance.yahoo.com - September 13 at 3:07 PM
Better Buy: Gilead Sciences, Inc. vs. BiogenBetter Buy: Gilead Sciences, Inc. vs. Biogen
finance.yahoo.com - September 13 at 3:07 PM
Why Analysts Remain Bullish on Sangamo TherapeuticsWhy Analysts Remain Bullish on Sangamo Therapeutics
finance.yahoo.com - September 13 at 3:07 PM
Sangamo Therapeutics: The Promise of Zinc FingersSangamo Therapeutics: The Promise of Zinc Fingers
finance.yahoo.com - September 13 at 3:07 PM
Gilead (GILD), Galapagos (GLPG) Announce Filgotinib Met Primary and All Key Secondary Endpoints in First Phase 3 Study in RAGilead (GILD), Galapagos (GLPG) Announce Filgotinib Met Primary and All Key Secondary Endpoints in First Phase 3 Study in RA
www.streetinsider.com - September 13 at 5:11 AM
Why Gilead, Galapagos Shares Are Trading HigherWhy Gilead, Galapagos Shares Are Trading Higher
www.msn.com - September 13 at 5:11 AM
Gileads Rheumatoid Arthritis Drug Successful in Phase IIIGilead's Rheumatoid Arthritis Drug Successful in Phase III
www.zacks.com - September 12 at 3:09 PM
Gilead Sciences Inc. (GILD) Is Rising On Phase 3 Study ResultsGilead Sciences Inc. (GILD) Is Rising On Phase 3 Study Results
www.nasdaq.com - September 12 at 3:09 PM
Gilead Sciences (GILD) Reports Collaboration with Precision BioSciences to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome EditingGilead Sciences (GILD) Reports Collaboration with Precision BioSciences to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
www.streetinsider.com - September 12 at 3:09 PM
Why Gilead Is Banking Big on Hepatitis B and Rheumatoid ArthritisWhy Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis
www.msn.com - September 12 at 3:09 PM
3 Top Stocks for Investing in Pharma's Next $35 Billion Market3 Top Stocks for Investing in Pharma's Next $35 Billion Market
finance.yahoo.com - September 12 at 3:09 PM
Incyte, Foundation Medicine Partner for Companion DiagnosticsIncyte, Foundation Medicine Partner for Companion Diagnostics
finance.yahoo.com - September 12 at 3:09 PM
US STOCKS-Wall St to open flat as trade worries linger; Apple event in focusUS STOCKS-Wall St to open flat as trade worries linger; Apple event in focus
finance.yahoo.com - September 12 at 3:09 PM
US STOCKS-Tech stocks weigh on Wall St, energy stocks help cut lossesUS STOCKS-Tech stocks weigh on Wall St, energy stocks help cut losses
finance.yahoo.com - September 12 at 3:09 PM
Merck's Antibacterial Drug Succeeds in Label Expansion StudyMerck's Antibacterial Drug Succeeds in Label Expansion Study
finance.yahoo.com - September 12 at 3:09 PM
Galapagos, Gilead bask in $4-6 billion new drug sales hopeGalapagos, Gilead bask in $4-6 billion new drug sales hope
finance.yahoo.com - September 12 at 3:09 PM
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR SoarsBiotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
finance.yahoo.com - September 12 at 3:09 PM
Here's Why Galapagos NV Is Skyrocketing 18.3% TodayHere's Why Galapagos NV Is Skyrocketing 18.3% Today
finance.yahoo.com - September 12 at 3:09 PM
Piper Jaffray Companies Analysts Give Gilead Sciences (GILD) a $85.00 Price TargetPiper Jaffray Companies Analysts Give Gilead Sciences (GILD) a $85.00 Price Target
www.americanbankingnews.com - September 12 at 10:42 AM
Gilead Sciences Reports Market-Moving NewsGilead Sciences Reports Market-Moving News
finance.yahoo.com - September 12 at 8:40 AM
Gilead Sciences Brings Strong Rheumatoid Arthritis Data, This Train Keeps RollingGilead Sciences Brings Strong Rheumatoid Arthritis Data, This Train Keeps Rolling
seekingalpha.com - September 12 at 5:04 AM
Drug succeeds in arthritis study, Gilead stock jumpsDrug succeeds in arthritis study, Gilead stock jumps
finance.yahoo.com - September 12 at 5:04 AM
Ex-Dividend Reminder: El Paso Electric, DTE Energy and Gilead SciencesEx-Dividend Reminder: El Paso Electric, DTE Energy and Gilead Sciences
www.nasdaq.com - September 11 at 3:06 PM
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel